Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Completed 1Active not recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Head & Neck 1Endocrine 1

Conditions

Carcinoma, Non-Small-Cell Lung 298Neoplasms 179Breast Neoplasms 170Colorectal Neoplasms 107Neoplasm Metastasis 100Melanoma 99Multiple Myeloma 93Prostatic Neoplasms 90Ovarian Neoplasms 83Recurrence 80Carcinoma, Renal Cell 73Lung Neoplasms 71Stomach Neoplasms 67Squamous Cell Carcinoma of Head and Neck 67Lymphoma, Non-Hodgkin 61Pancreatic Neoplasms 59Leukemia, Lymphocytic, Chronic, B-Cell 56Leukemia, Myeloid, Acute 54Carcinoma, Hepatocellular 48Triple Negative Breast Neoplasms 47Small Cell Lung Carcinoma 46Urinary Bladder Neoplasms 45Lymphoma, Large B-Cell, Diffuse 43Head and Neck Neoplasms 41Endometrial Neoplasms 41Lymphoma, Follicular 39Lymphoma 37Uterine Cervical Neoplasms 35Parkinson Disease 4, Autosomal Dominant Lewy Body 34Glioblastoma 34

Interventions

trametinib 1dabrafenib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Active not recruiting × INDUSTRY × Differentiated Thyroid Cancer (DTC) × Clear all
NCT04940052 2026-06-04

Study of Efficacy and Safety of Dabrafenib in Combination With Trametinib in Previously Treated Patients With Metastatic, Radio-active Iodine Refractory BRAF V600E Mutation Positive Differentiated Thyroid Cancer

Novartis

Phase 3 Active not recruiting
153 enrolled 15 charts
EndocrineHead & Neck

Differentiated Thyroid Cancer (DTC)

Data powered by HemOnc (CC BY 4.0) Colophon âš¡